These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6848127)

  • 1. Idiopathic autoantibody that inhibits fibrin monomer polymerization.
    Ghosh S; McEvoy P; McVerry BA
    Br J Haematol; 1983 Jan; 53(1):65-72. PubMed ID: 6848127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A naturally occurring antibody that inhibits fibrin polymerization.
    Hoots WK; Carrell NA; Wagner RH; Cooper HA; McDonagh J
    N Engl J Med; 1981 Apr; 304(15):857-61. PubMed ID: 7207522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody to plasma fibrinopeptide A in a patient with a severe acquired haemorrhagic syndrome.
    Gris JC; Schved JF; Branger B; Aguilar-Martinez P; Vécina F; Oulès R; Sarlat C; Fourcade J
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):519-29. PubMed ID: 1450318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired Dysfibrinogenemia Caused by Autoantibody Inhibiting Fibrin Polymerization in a Patient with MELAS Syndrome and Bleeding Tendency.
    Lee N; Kim JE; Yoo HJ; Gu J; Kim H; Chung J; Koh Y; Kim HK
    Ann Clin Lab Sci; 2016 Dec; 46(6):696-700. PubMed ID: 27993886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An acquired inhibitor that produced a delay of fibrinopeptide B release in an asymptomatic patient.
    Llobet D; Borrell M; Vila L; Vallvé C; Felices R; Fontcuberta J
    Haematologica; 2007 Feb; 92(2):e17-9. PubMed ID: 17405747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen Houston: a dysfibrinogen exhibiting defective fibrin monomer aggregation and alpha-chain cross-linkages.
    Weinger RS; Rudy C; Moake JL; Conlon CL; Cimo PL
    Am J Hematol; 1980; 9(3):237-48. PubMed ID: 6165239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.
    Al-Mondhiry H; Galanakis D
    J Lab Clin Med; 1987 Dec; 110(6):726-33. PubMed ID: 3119749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysfibrinogenemia associated with liver disease.
    Palascak JE; Martinez J
    J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release.
    Nawarawong W; Wyshock E; Meloni FJ; Weitz J; Schmaier AH
    Br J Haematol; 1991 Oct; 79(2):296-301. PubMed ID: 1958489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An abnormal inherited fibrinogen (fibrinogen Genova) with delayed fibrin aggregation.
    Hassan HJ; Orlando M; Tonini GP; Casalbore P; Sarti A; Boeri E; Giacchino R; Tentori L; Mori PG
    Scand J Haematol; 1982 Oct; 29(4):287-94. PubMed ID: 7178834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An acquired cryoglobulinemia which inhibits fibrin polymerization in a patient with IgG kappa myeloma.
    Panzer S; Thaler E
    Haemostasis; 1993; 23(1):69-76. PubMed ID: 8477911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
    Lane DA; Cuddigan B; VanRoss M; Kakkar VV
    Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen Matsumoto V: a variant with Aalpha19 Arg-->Gly (AGG-->GGG). Comparison between fibrin polymerization stimulated by thrombin or reptilase and fibrin monomer polymerization.
    Tanaka H; Terasawa F; Ito T; Tokunaga S; Ishida F; Kitano K; Kiyosawa K; Okumura N
    Thromb Haemost; 2001 Jan; 85(1):108-13. PubMed ID: 11204560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
    Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
    Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired coagulation inhibitor delaying fibrinopeptide release.
    Marciniak E; Greenwood MF
    Blood; 1979 Jan; 53(1):81-92. PubMed ID: 758215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: influence of inhibitors of fibrin polymerization.
    Ruf W; Bender A; Lane DA; Preissner KT; Selmayr E; Müller-Berghaus G
    Biochim Biophys Acta; 1988 May; 965(2-3):169-75. PubMed ID: 3365451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of fibrin monomer polymerization by Bence Jones protein in a patient with primary amyloidosis.
    Shigekiyo T; Kosaka M; Shintani Y; Azuma H; Iishi Y; Saito S
    Acta Haematol; 1989; 81(3):160-5. PubMed ID: 2496565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfibrinogenaemia associated with a defect in the aggregation of the fibrin monomers (Almeria I fibrinogen). A preliminary study.
    Vila V; Regañon E; Fernandez-Pavon A; Aznar J
    Scand J Haematol; 1984 Nov; 33(5):460-5. PubMed ID: 6515329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Disorders in the conversion of fibrinogen to fibrin in patients with multiple myeloma].
    Lopaciuk S; Snigurowicz J; Rostkowska J; Pniejnia-Olszyński W; Powiertowska-Rezmer M
    Acta Haematol Pol; 1978; 9(3):157-64. PubMed ID: 102100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
    Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
    Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.